Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease
- 18 October 2006
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2006 (4), CD006257
- https://doi.org/10.1002/14651858.cd006257
Abstract
Background Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (AIIRA) are considered to be equally effective for patients with diabetic kidney disease ( DKD), but renal and not mortality outcomes have usually been considered. Objectives To evaluate the benefits and harms ACEi and AIIRA in patients with DKD. Search strategy We searched MEDLINE ( 1966 to December 2005), EMBASE ( 1980 to December 2005), the Cochrane Central Register of Controlled Trials ( CENTRAL, The Cochrane Library issue 4 2005) and contacted known investigators. Selection criteria Studies comparing ACEi or AIIRA with placebo or each other in patients with DKD were included. Data collection and analysis Two authors independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and results expressed as relative risk (RR) with 95% confidence intervals (CI). Heterogeneity among studies was explored using the Cochran Q statistic and the I-2 test, subgroup analyses and random effects metaregression. Main results Fifty studies ( 13,215 patients) were identified. Thirty eight compared ACEi with placebo, five compared AIIRA with placebo and seven compared ACEi and AIIRA directly. There was no significant difference in the risk of all-cause mortality for ACEi versus placebo ( RR 0.91, 95% CI 0.71 to 1.17) and AIIRA versus placebo (RR 0.99, 95% CI 0.85 to 1.17). A subgroup analysis of studies using full-dose ACEi versus studies using half or less than half the maximum tolerable dose of ACEi showed a significant reduction in the risk of all-cause mortality with the use of full-dose ACEi ( RR 0.78, 95% CI 0.61 to 0.98). Baseline mortality rates were similar in the ACEi and AIIRA studies. The effects of ACEi and AIIRA on renal outcomes (ESKD, doubling of creatinine, prevention of progression of micro-to macroalbuminuria, remission of micro- to normoalbuminuria) were similarly beneficial. Reliable estimates of effect of ACEi versus AIIRA could not be obtained from the three studies in which they were compared directly because of their small sample size. Authors' conclusions Although the survival benefits of ACEi are known for patients with DKD, the relative effects on survival of ACEi with AIIRA are unknown due to the lack of adequate direct comparison studies. In placebo controlled studies, only ACEi ( at the maximum tolerable dose, but not lower so-called renal doses) were found to significantly reduce the risk of all-cause mortality. Renal and toxicity profiles of these two classes of agents were not significantly different.Keywords
This publication has 96 references indexed in Scilit:
- Effect of Treatment With Candesartan or Enalapril on Subcutaneous Small Artery Structure in Hypertensive Patients With Noninsulin-Dependent Diabetes MellitusHypertension, 2005
- Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)BMJ, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Measuring inconsistency in meta-analysesBMJ, 2003
- Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathyClinical and Experimental Nephrology, 2003
- Nephropathy in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 1999
- Effects of Lisinopril and Nifedipine on the Progression to Overt Albuminuria in IDDM Patients With Incipient Nephropathy and Normal Blood PressureDiabetes Care, 1998
- Effects of Long-Term Enalapril Treatment on Persistent Microalbuminuria in Well-Controlled Hypertensive and Normotensive NIDDM PatientsDiabetes Care, 1994
- Microalbuminuria and ACE inhibition in non-hypertensive diabeticsJournal of Diabetic Complications, 1990
- Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.BMJ, 1988